Eribulin Mesylate-based Therapy in Patients With Advanced HER2-negative Breast Cancer Previously Treated With ADC

Starting soon

Conditions studied: Treatment Efficacy

In brief

This study is a real-world study. we collected patients with advanced HER2-negative breast cancer previously treated with antibody-drug conjugates, and received eribulin mesylate-based therapy post-ADC. We retrospectively collect the data on previous systemic treatment, and prospectively collect the treatment data of the therapeutic regimens based on eribulin mesylate.

Key facts

Study ID

NCT07480694

Run by

Fudan University

People needed

400

Starts

2026-03-01

Expected to finish

2028-02-01

Last updated by the study team

2026-03-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least 18 years old;
• Inoperable locally advanced or metastatic breast cancer;
• Planning to use a single-agent or combination treatment regimen based on eribulin;
• HER2 negative (IHC 0,+, or ++ but ISH negative);
• Previously received ADC treatment at the local advanced or metastatic disease stage;
• Previously received chemotherapy (including ADC) for local advanced or metastatic disease no more than 2 lines, where one treatment line is defined as completing at least one cycle of chemotherapy;
• Eastern Cooperative Oncology Group (ECOG) performance status score (PS) 0-2;
• The investigators have evaluated that the patient's organ and bone marrow functions are suitable for medication use and there are no relevant contraindications;
• The subjects voluntarily join the study and sign the informed consent.

You may not qualify if…

• HER2-positive tumors
• The hormone receptor status is unknown;
• Patients who have received eribulin treatment before;
• Those who have had other malignant tumors within the past 5 years (excluding the following situations: cured skin basal cell carcinoma, cervical carcinoma in situ, papillary thyroid carcinoma; second primary cancer that has been cured and has no recurrence within 5 years; subjects who have clearly identified the origin of the metastatic lesion as being from a certain primary tumor);
• Mental illness or mental disorder, patients with poor compliance and inability to cooperate and describe treatment responses;
• Pregnant or lactating women;
• Other serious or uncontrollable diseases, or other conditions assessed by the researcher as not suitable for enrollment.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.